CTOs on the Move

adMare BioInnovations

www.admarebio.com

 
Canada’s Global Life Sciences Venture / Partenaire d’affaires en sciences de la vie au Canada #lifesciences #biotech #sante
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.admarebio.com
  • 2405, Wesbrook Mall
    Vancouver, BC CAN V6T 1Z3
  • Phone: 604.827.1147

Executives

Name Title Contact Details

Similar Companies

PharmaExpressRx

PharmaExpressRx is a Addison, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).

Alpharma Integrated Solutions

Alpharma Integrated Solutions is a Vega Baja, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.